Akili, Inc. specializes in digital therapeutics, focusing on developing video game-based treatments for cognitive disorders, particularly ADHD. Its proprietary product, EndeavorRx, is the first FDA-approved prescription video game, providing a unique competitive edge in the growing digital health market.
Business Overview
Akili generates revenue primarily through the sale of its digital therapeutic product, EndeavorRx, which is marketed to healthcare providers and patients. The company leverages its FDA approval as a significant competitive advantage, allowing it to command higher pricing power in a niche market.
FDA regulatory approvals for new indications of EndeavorRx
Partnerships with healthcare providers and payers to expand market access
Clinical trial results demonstrating efficacy for additional cognitive disorders
Market adoption rates of digital therapeutics in the healthcare system
Risk Factors
Regulatory changes affecting digital therapeutics approval processes
Technological disruption from emerging competitors in the digital health space
Increased competition from other digital therapeutic companies
Potential for traditional pharmaceutical companies to enter the digital health market
High operating losses leading to cash flow concerns
Dependence on external funding for ongoing R&D
Macro Sensitivity
moderate - As a healthcare service, demand for digital therapeutics may remain stable during economic downturns, but broader healthcare spending trends can impact growth.
Interest rates affect the company's cost of capital for R&D investments and may influence healthcare spending; higher rates could dampen growth expectations.
minimal - The company has a manageable debt-to-equity ratio of 0.26, indicating limited reliance on credit.
Profile
growth - Investors looking for high-growth opportunities in the digital health sector will find Akili appealing.
high - The stock has shown significant volatility, evidenced by a 1-year return of -63.6%.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
